PR Newswire·Nov 4, 2025, 4:05 PM ET

Cryoport Reports Third Quarter 2025 Financial Results

CYRX

Cryoport reported third quarter 2025 revenue of $44.2 million, a 15% increase year-over-year.
Commercial Cell & Gene Therapy revenue rose 36% year-over-year to $8.3 million.
Life Sciences Services revenue grew 16% year-over-year to $24.3 million, with BioStorage/BioServices revenue up 21% to $4.8 million.
Life Sciences Products revenue increased 15% year-over-year to $20.0 million.
Total revenue for the first nine months of 2025 reached $130.7 million, a 13% increase compared to the same period in 2024.
The company raised its full-year 2025 revenue guidance for continuing operations to a range of $170.0 million to $174.0 million.
Gross margin from continuing operations was 48.2% in Q3 2025, up from 45.5% in Q3 2024.
Adjusted EBITDA from continuing operations was a negative $0.6 million for Q3 2025, an improvement from a negative $2.7 million in Q3 2024.
Cryoport supported 745 global clinical trials as of September 30, 2025, including 83 in Phase 3.
The company launched a new Global Supply Chain Center near Charles de Gaulle Airport in Paris, France.
MVE Biological Solutions introduced next-generation dry vapor shippers equipped with integrated Condition Monitoring Solutions.
Cryoport completed the divestiture of its CRYOPDP business to DHL in June 2025, establishing a strategic partnership to expand in EMEA & APAC regions.
Net loss attributable to common stockholders was $8.9 million in Q3 2025, while net income for the first nine months was $83.9 million driven by discontinued operations gains.
As of September 30, 2025, the company held $421.3 million in cash, cash equivalents, & short-term investments.
During Q3 2025, the company repurchased 483,397 shares of common stock for an aggregate amount of $3.7 million.